AGN Loosens Purse Strings FCSC Gears Up For Phase 2 Data Big Gains For Viveve

The last patient visit for primary endpoint analysis has been completed in Fibrocell Science Inc.'s (FCSC) phase II trial of Azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia.

from RTT - Biotech http://ift.tt/1SnIFtu
via IFTTT